Who the enrolling study is looking for — and the geography that decides whether you can take part.
These studies are recruiting through partner research networks. We may be paid a referral fee if you complete their screening form — this never changes what you pay (nothing) or the compensation the study offers you.
This study is enrolling adults in eligible areas of the United States who have been diagnosed with heart failure. The study team confirms eligibility and any compensation before enrollment.
Screening is free and takes a few minutes. Eligibility and any compensation are confirmed by the study team, not by this site.
More than six million adults in the United States live with heart failure — a diagnosis that means the heart is not pumping as well as it should, not that it has stopped. It is one of the most heavily researched conditions in medicine, because current treatments manage the condition rather than reverse it, and that gap is exactly what investigational therapies are trying to close.
A study is currently enrolling US adults who have been diagnosed with heart failure. It runs from a limited number of investigator sites, which makes geography the first filter: this page covers who the study is looking for, what screening involves, and which metros are within reach of an active site.
The headline criterion is a physician diagnosis of heart failure. Suspecting a heart problem, or having been told your blood pressure is high, is not the same thing — screening will ask for the diagnosis, and the study team verifies it against your medical records before anything else happens.
Heart failure is not one uniform condition, and protocols in this area typically care about the details behind the diagnosis:
Which of these applies to the currently enrolling study is established on the screening call, not on the form. If you have a heart failure diagnosis, the honest summary is: you are the population this study is recruiting from, and the details get worked out with the coordinator.
Like a number of studies we list, this one runs from a small set of investigator sites rather than nationwide — currently clustered around the Washington DC area, the North Carolina Research Triangle, Cincinnati, eastern Nebraska, and Denver. Participation means travelling to a site for visits, so being within reach of one is a hard requirement no medical criterion can override.
The metros listed further down are the ones inside the paid recruitment zone — roughly a 30-mile radius around each site. If you are outside them, this particular study is not available to you, and it is better to know that before filling in a form than after three screening steps.
Heart research overall is anything but narrow, though: cardiovascular studies appear in nearly every large metro we track. Our per-city pages list every study recruiting within 30 miles, straight from the NIH registry, and heart and vascular research is one of the most active categories on almost all of them.
Screening runs in the usual stages: a short online form checks the headline criteria, a coordinator calls to go through your cardiac history and medications, and an in-person screening visit follows if it still looks like a fit — typically with bloodwork, an ECG, and often an echocardiogram to measure ejection fraction.
Two things worth knowing going in. First, never adjust or stop your current heart medication to qualify for a study — no legitimate protocol asks you to do that on your own, and any change happens under the study physician's supervision if it happens at all. Second, screening failure is common in cardiology studies because measurements have to land inside a defined window; being screened out says nothing about how well managed your condition is.
Screening is free at every stage. Compensation for time and travel is set by each study's protocol, reviewed by an ethics board, and disclosed in writing before you enroll — across US research generally, payments run from $75 to $4,500 per completed study depending on visit count and procedures.
Join the free email alert — we watch the NIH registry weekly so you don't have to.
Get trial alertsCardiology listings lean on abbreviations that are worth being able to parse before a screening call:
Your most recent echocardiogram report contains most of these numbers. Having it to hand makes the screening call substantially shorter.
Yes. The enrolling study requires a physician diagnosis of heart failure, and the study team verifies it against medical records during screening. If you have symptoms but no diagnosis, the first step is a cardiologist, not a study.
It can. Studies typically target either reduced-EF (HFrEF) or preserved-EF (HFpEF) heart failure rather than both. Which one the currently enrolling study targets is established on the screening call — knowing your most recent ejection fraction number speeds that conversation up considerably.
Not on your own, ever. Study treatments in heart failure are generally evaluated on top of standard care, and any medication change happens under the study physician's supervision after enrollment, if at all. A protocol asking you to stop treatment before screening is a red flag.
This particular study recruits within roughly 30 miles of its investigator sites, so distance is a hard limit. Cardiovascular research more broadly is among the most active categories in nearly every large US metro — your nearest city page lists everything recruiting within 30 miles from the NIH registry.
This study runs from a limited number of sites; these are the metros within reach
Get an email when a new clinical trial starts recruiting within 30 miles of your ZIP code. No spam — only real studies from the NIH registry.